What makes ADHD hard to diagnose in girls and women?

Girls with ADHD are more likely to have the inattentive subtype — daydreaming, careless mistakes, forgetfulness — rather than the hyperactive-disruptive presentation that prompts teacher referrals. Girls also tend to internalise, presenting with anxiety and low self-esteem rather than conduct problems. High-effort cognitive masking — extended preparation, extensive list-making, running on adrenaline to simulate neurotypical performance — postpones recognition until coping capacity is exhausted. Comorbid anxiety and depression are frequently diagnosed first, delaying recognition of the underlying ADHD. The woman who receives a diagnosis after her child is identified is a common general practice presentation.

How does the menstrual cycle affect ADHD symptoms?

Oestrogen enhances dopamine and noradrenaline signalling — the neurotransmitters most relevant to ADHD. When oestrogen falls in the luteal phase, many women with ADHD experience worsening inattention, emotional dysregulation, and impulsivity that substantially overlaps with PMDD. In the follicular phase, when oestrogen is rising, symptoms are typically milder. Women who track their cognition and mood across the cycle often recognise a cyclical pattern well before they seek assessment. The same mechanism explains why perimenopause — with declining oestrogen — can trigger first-time ADHD presentation or dramatically worsen existing symptoms in women aged 40–55 years.

What is the diagnostic pathway for adult women in Australia?

The GP's role is to screen, exclude mimics, and refer — formal diagnosis requires specialist assessment. Screen using the ASRS v1.1 (6-item Part A; ≥4 positive answers suggests likely ADHD) and take a collateral history from a partner or parent. Order mimic-exclusion bloods: ferritin, TSH, B12, vitamin D, and a sleep screen for obstructive sleep apnoea. Make a Mental Health Care Plan under MBS item 2715 or 2717 and refer to an adult psychiatrist (or paediatrician for adolescents) for a DIVA-5-based diagnostic interview. Public wait times can be 6–24 months; private services typically 1–6 months.

What medications are used, and who can prescribe them in Australia?

First-line pharmacotherapy is stimulant medication: lisdexamfetamine (Vyvanse, 30–70 mg morning, preferred for its smoother profile and lower diversion risk) or methylphenidate (Ritalin IR or modified-release, Concerta 18–54 mg). Both are Schedule 8 controlled drugs requiring state Health Department authority and specialist initiation. GPs can continue prescriptions under a shared-care arrangement. Non-stimulant atomoxetine (Strattera) is PBS-listed and useful when stimulants are contraindicated — active eating disorder with low BMI, cardiovascular risk, or concurrent substance use disorder. All Schedule 8 stimulant prescriptions are monitored through SafeScript or equivalent real-time prescription monitoring.

What comorbidities are more common in women with ADHD?

Women with ADHD have higher rates of comorbidity than men. Anxiety disorders affect approximately 60–70%, major depressive disorder approximately 50–60%, and eating disorders — binge eating, anorexia, bulimia — approximately 30–40%. PMDD is substantially overrepresented. Suicidality and self-harm risk is elevated four to six times above the general population rate, which mandates systematic assessment at every mental health contact. Sleep disorders — particularly insomnia and obstructive sleep apnoea — are common. ASD overlap is well recognised. A new ADHD diagnosis warrants concurrent screening for mood disorder, eating disorder, sleep disorder, and suicide risk.

What non-medication strategies help alongside stimulant treatment?

CBT for ADHD — adapted protocols targeting executive function, emotion regulation, and time management — has moderate evidence and is fundable through Better Access psychology (MBS 80000–80020). ADHD coaching offers practical accountability and skill-building. Sleep optimisation is high yield: sleep debt amplifies inattention and emotional dysregulation. Regular aerobic exercise has a demonstrated acute benefit on attention. Iron, B12, and vitamin D correction matters particularly in menstruating women where deficiency is common. For cycle-sensitive women, managing PMDD with a luteal-phase SSRI or oestrogen-containing contraception can substantially reduce cyclical symptom worsening.

ADHD in females

ADHD in girls and women: recognition and management in AU general practice

By Dr HB Lo, FACRRM Reviewed 28 June 2026 9 min read

ADHD affects girls and women at roughly equal rates to men, yet childhood diagnosis is three to four times less common. The gap closes in adulthood as inattentive symptoms and high-effort masking exhaust coping capacity.

The AADPA 2022 guideline (RANZCP-endorsed April 2024) is the Australian standard. GP role: ASRS v1.1 screen, mimic exclusion, Mental Health Care Plan, then psychiatrist referral for DIVA-5 diagnosis. Stimulants need state Schedule 8 authority.

Oestrogen drives dopamine signalling, making ADHD cycle-sensitive: worse premenstrually, at perimenopause, and postpartum. Cycle-aware management improves day-to-day function.

ADHD (Attention Deficit Hyperactivity Disorder, DSM-5 F90) is a neurodevelopmental condition affecting approximately 3–5% of Australian adults. Childhood prevalence is broadly similar between sexes, yet girls are diagnosed three to four times less often than boys — a discrepancy that reflects structural barriers in how ADHD presents in females, not a genuine difference in prevalence.

By adulthood, the diagnostic ratio approaches 1:1. This means that tens of thousands of Australian women live with undiagnosed ADHD. Late diagnosis carries cumulative harm: under-employment, financial difficulty, relationship strain, comorbid depression, eating disorders, and elevated self-harm and suicidal ideation risk.

The AADPA 2022 Australian Evidence-Based Clinical Practice Guideline for ADHD — endorsed by RANZCP in April 2024 — is the current Australian standard. GPs play a critical role: taking the initial screen, ordering mimic-exclusion investigations, making the Mental Health Care Plan, and managing shared-care prescribing once a specialist has initiated treatment.

A. Core clinical — the AU general-practice framework

Diagnostic criteria and GP role

ADHD diagnosis requires (DSM-5):

≥6 inattentive and/or ≥6 hyperactive-impulsive symptoms (≥5 in adults aged ≥17 years)
Symptom onset before age 12
Impairment in ≥2 settings
Functional impairment in social, academic, or occupational domains
Not better explained by another mental health condition

The GP role is to screen, exclude mimics, and refer:

Screen using the ASRS v1.1 — the WHO-validated 6-item Part A screen; ≥4 positive items indicates high likelihood
Take a comprehensive history including collateral (parent, partner, old school reports)
Order investigations to exclude organic mimics (below)
Make a Mental Health Care Plan (MBS 2715/2717) and refer to an adult psychiatrist or paediatrician (for adolescents) for formal diagnostic interview
Manage shared-care prescribing and monitoring once the specialist has initiated treatment

Mimic exclusion investigations

Order before referring — these strengthen the referral and rule out treatable contributors:

Investigation	Rationale
FBC	Iron-deficiency anaemia mimics inattention and fatigue
Ferritin / iron studies	Ferritin <30 µg/L in a menstruating woman amplifies inattention independently
TSH	Hypothyroidism or hyperthyroidism
B12 and folate	Deficiency causes cognitive impairment
Vitamin D	Low 25(OH)D found commonly with fatigue and cognitive slowing
HbA1c / fasting glucose	Diabetes or hypoglycaemia
UEC, LFT	General screen
OSA screen (STOP-Bang + Epworth)	OSA is highly comorbid and independently causes inattention and daytime fatigue; sleep study MBS 12203 if indicated
Mood screen (PHQ-9, GAD-7, MDQ)	Anxiety, depression, bipolar — stimulants destabilise bipolar; MDQ is essential before initiation
ECG (MBS 11707)	Mandatory before stimulant initiation; screens for congenital long QT, WPW, structural disease

Specialist assessment

The DIVA-5 (Diagnostic Interview for ADHD in Adults) is the gold-standard structured interview, administered by a psychiatrist or specialist. It covers current symptoms and childhood evidence systematically with informant input. Collateral — ideally childhood school reports or a parent completing a structured history — is sought at this stage. Diagnosis is not made by the GP.

B. Why females are under-recognised — the masking pattern

Understanding the mechanisms of under-recognition helps GPs maintain a lower clinical threshold when assessing women and girls presenting with fatigue, anxiety, or treatment-resistant depression.

Mechanism	Clinical signature
Predominantly inattentive subtype	Daydreaming, careless mistakes, losing belongings, chronic disorganisation — overlooked at school because not disruptive (AADPA 2022)
Internalising over externalising	Anxiety and depression attract clinical attention first; ADHD missed underneath (Quinn 2014)
Cognitive masking	High-effort compensating — late-night catch-up, extensive lists, enormous effort to appear functional — postpones recognition until coping capacity is exhausted
Social camouflage	Modelling neurotypical peers; deeply exhausting; identity confusion emerging in late teens and twenties
Rejection-sensitive dysphoria	Intense cyclical emotional reactivity to perceived rejection or failure; often coded as anxiety or borderline traits rather than ADHD
Referral filter bias	Historically, teachers referred disruptive boys; quiet inattentive girls were overlooked by the system built around them

A particularly common general practice presentation: a woman who seeks help after her child is diagnosed with ADHD, recognising the description in herself. This back-door pattern accounts for a substantial proportion of adult female ADHD presentations (Quinn 2014).

Comorbidities more prevalent in women with ADHD (Faraone 2024):

Anxiety disorders ~60–70%
Major depressive disorder ~50–60%
Eating disorders (binge eating, anorexia, bulimia) ~30–40%
PMDD — substantially overrepresented
Chronic insomnia and obstructive sleep apnoea
Suicidality and self-harm: elevated four to six times above general population

The elevated suicidality risk — documented in prospective cohort data by Hinshaw 2012 — makes ADHD in women a condition requiring systematic suicide and self-harm assessment at every mental health contact.

C. Hormonal modulation across the female lifespan

Oestrogen upregulates dopamine and noradrenaline signalling — the neurotransmitter systems most relevant to ADHD. This makes ADHD a uniquely oestrogen-sensitive neurodevelopmental condition in women, with symptom severity tracking hormonal flux across the reproductive lifespan (Roberts 2023).

Premenstrual (luteal) phase: Oestrogen falls in the luteal phase → dopamine signalling decreases → ADHD symptoms typically worsen. High overlap with PMDD. Women who chart their mood and cognition often recognise a cyclical pattern before they have an ADHD diagnosis. The AADPA 2022 guideline explicitly notes this oestrogen-ADHD interaction; however, cycle-aware dose adjustment is not yet formally protocolised and remains specialist territory.

Perimenopause and menopause: Declining oestrogen in the perimenopausal years can trigger first-time recognition or dramatic escalation of existing ADHD in women aged 40–55. Women presenting with new-onset executive dysfunction, emotional dysregulation, forgetfulness, and mood lability — particularly where these symptoms are disproportionate to “typical” perimenopausal presentations — warrant ADHD assessment. Menopausal hormone therapy may improve ADHD symptom control by restoring oestrogen-dopamine signalling; this is supported by biological plausibility and clinical practice (Eng 2024; AMS information sheets) but lacks RCT-level evidence as an ADHD-specific intervention.

Pregnancy and postpartum: Lisdexamfetamine and methylphenidate are Category B3 (no demonstrated human fetal harm in available data; limited human studies). Discontinuation before conception is the standard approach; continuation in pregnancy requires specialist review weighing functional impairment risk against theoretical fetal risk. Postpartum oestrogen withdrawal combined with sleep deprivation frequently worsens ADHD. Perinatal psychiatry liaison is appropriate for women with diagnosed ADHD planning pregnancy or in the postpartum period.

D. Australian operations

Medications and Schedule 8 framework

In Australia, stimulant medications for ADHD are Schedule 8 (controlled drugs). Prescribing requires:

Specialist diagnosis — adult psychiatrist, paediatrician (for adolescents), or other approved clinician
State Health Department Schedule 8 authority — varies by jurisdiction; most states require specialist initiation, with GP shared-care prescribing possible under the specialist’s treatment plan

First-line pharmacotherapy per AADPA 2022:

Agent	Dose	Notes
Lisdexamfetamine (Vyvanse)	30–70 mg morning	Pro-drug; smoother, longer profile; lower abuse potential; PBS Authority Required
Methylphenidate IR (Ritalin)	10 mg twice to three times daily	Titrate to response; PBS Authority Required
Methylphenidate SR (Concerta, Ritalin LA)	18–54 mg morning	Modified release; PBS Authority Required

Non-stimulant options (when stimulant is contraindicated):

Atomoxetine (Strattera 40–100 mg) — useful in active substance use disorder, severe anxiety, eating disorder with low BMI, cardiovascular concern; PBS Authority Required
Guanfacine ER (Intuniv) — PBS paediatric only; adult use is off-label

Safety monitoring per AMH and eTG: BP, HR, weight, mental state, sleep, appetite, and SafeScript review at every contact. Fortnightly during titration; three-monthly once stable.

MBS pathway

Item	Purpose
23 / 36 / 44	Standard GP consultation
2715 / 2717	Mental Health Care Plan (≥20 min/≥40 min)
2712	MHCP review
80000–80020	Better Access psychology — 10 + up to 10 sessions/year
132 / 133	Psychiatrist initial and subsequent
11707	ECG — mandatory before stimulant initiation
12203	Sleep study if OSA is suspected

Australian consumer and clinical resources

ADHD Australia — peak advocacy organisation; navigating diagnosis, support groups
AADPA consumer hub — guideline-linked patient information
Jean Hailes for Women’s Health — women-specific ADHD resources
Beyond Blue — comorbid mood disorder support
Butterfly Foundation 1800 33 4673 — eating disorder comorbidity
Lifeline 13 11 14 — crisis support

E. Special populations

Adolescents transitioning to adult care. The transition from paediatric to adult ADHD services is a high-risk period. Many young women experience a deterioration at university — the scaffolded school environment gives way to self-directed study; masking capacity is depleted; social demands amplify emotional dysregulation. GPs can bridge the gap by maintaining shared-care prescriptions, updating Mental Health Care Plans, and facilitating referral to adult psychiatry before the paediatric provider discharges the young person.

Perimenopausal women. A woman aged 40–55 with worsening cognition, emotional dysregulation, and forgetfulness not fully explained by vasomotor symptoms, sleep disruption, or depressed mood warrants a formal ADHD assessment or re-assessment of known ADHD. Both ADHD and perimenopause benefit from the same lifestyle foundation: restorative sleep, aerobic exercise, alcohol reduction, and structured routine. Menopausal hormone therapy is a reasonable adjunct in symptomatic women where oestrogen deficiency is contributing to symptom worsening.

Women planning pregnancy or breastfeeding. Stimulant discontinuation before conception is standard; the decision to continue must involve an adult psychiatrist and obstetrician, with careful documentation of the risk-benefit discussion. Most stimulants pass into breast milk; specialist input is needed before continuing postpartum.

Eating disorder comorbidity. Stimulants are contraindicated in active anorexia (BMI <17.5) and in patients with active purging behaviours. Screen all women seeking ADHD treatment with a brief eating disorder screen (SCOFF or similar). When an eating disorder is present, it takes clinical priority; atomoxetine may be a safer pharmacological option when the eating disorder is partially stabilised. Butterfly Foundation has resources on co-occurring ADHD and eating disorders.

ATSI women. Aboriginal and Torres Strait Islander women experience higher rates of behavioural and neurodevelopmental conditions alongside significant healthcare access barriers. The 715 Health Assessment MBS 715 can provide a structured opportunity to screen for ADHD, mental health comorbidities, and social determinants of health in this population.

When to escalate

Urgent — emergency department or mental health crisis team — active suicidality or self-harm, severe eating disorder crisis, postpartum psychosis, or cardiovascular event on stimulant
Same-week psychiatric review — pregnancy on stimulant, MDQ-positive for bipolar disorder, severe functional breakdown preventing work or care of dependants
Routine psychiatry — initial formal diagnosis, complex comorbidity (ASD + ADHD, treatment-resistant depression), stimulant non-response, perimenopausal escalation requiring specialist input
Adolescent psychiatry or paediatrics — formal diagnosis under 18 years; transition-to-adult services planning
Perinatal psychiatry — pregnancy planning on stimulants, postpartum ADHD management

What this article is and is not

This is general health information based on current Australian guidelines — the AADPA 2022 Evidence-Based Clinical Practice Guideline for ADHD (RANZCP-endorsed 2024), Therapeutic Guidelines Psychotropic, Australian Medicines Handbook, and supporting peer-reviewed evidence. It is not a substitute for formal psychiatric diagnostic assessment. ADHD diagnosis in Australia requires specialist assessment; GPs screen and refer rather than diagnose.

For immediate support: Lifeline 13 11 14 or Beyond Blue 1300 22 4636. For eating disorder support: Butterfly Foundation 1800 33 4673. For ADHD peer community: ADHD Australia.

Sources cited

Frequently asked questions

What makes ADHD hard to diagnose in girls and women?

Girls with ADHD are more likely to have the inattentive subtype — daydreaming, careless mistakes, forgetfulness — rather than the hyperactive-disruptive presentation that prompts teacher referrals. Girls also tend to internalise, presenting with anxiety and low self-esteem rather than conduct problems. High-effort cognitive masking — extended preparation, extensive list-making, running on adrenaline to simulate neurotypical performance — postpones recognition until coping capacity is exhausted. Comorbid anxiety and depression are frequently diagnosed first, delaying recognition of the underlying ADHD. The woman who receives a diagnosis after her child is identified is a common general practice presentation.
How does the menstrual cycle affect ADHD symptoms?

Oestrogen enhances dopamine and noradrenaline signalling — the neurotransmitters most relevant to ADHD. When oestrogen falls in the luteal phase, many women with ADHD experience worsening inattention, emotional dysregulation, and impulsivity that substantially overlaps with PMDD. In the follicular phase, when oestrogen is rising, symptoms are typically milder. Women who track their cognition and mood across the cycle often recognise a cyclical pattern well before they seek assessment. The same mechanism explains why perimenopause — with declining oestrogen — can trigger first-time ADHD presentation or dramatically worsen existing symptoms in women aged 40–55 years.
What is the diagnostic pathway for adult women in Australia?

The GP's role is to screen, exclude mimics, and refer — formal diagnosis requires specialist assessment. Screen using the ASRS v1.1 (6-item Part A; ≥4 positive answers suggests likely ADHD) and take a collateral history from a partner or parent. Order mimic-exclusion bloods: ferritin, TSH, B12, vitamin D, and a sleep screen for obstructive sleep apnoea. Make a Mental Health Care Plan under MBS item 2715 or 2717 and refer to an adult psychiatrist (or paediatrician for adolescents) for a DIVA-5-based diagnostic interview. Public wait times can be 6–24 months; private services typically 1–6 months.
What medications are used, and who can prescribe them in Australia?

First-line pharmacotherapy is stimulant medication: lisdexamfetamine (Vyvanse, 30–70 mg morning, preferred for its smoother profile and lower diversion risk) or methylphenidate (Ritalin IR or modified-release, Concerta 18–54 mg). Both are Schedule 8 controlled drugs requiring state Health Department authority and specialist initiation. GPs can continue prescriptions under a shared-care arrangement. Non-stimulant atomoxetine (Strattera) is PBS-listed and useful when stimulants are contraindicated — active eating disorder with low BMI, cardiovascular risk, or concurrent substance use disorder. All Schedule 8 stimulant prescriptions are monitored through SafeScript or equivalent real-time prescription monitoring.
What comorbidities are more common in women with ADHD?

Women with ADHD have higher rates of comorbidity than men. Anxiety disorders affect approximately 60–70%, major depressive disorder approximately 50–60%, and eating disorders — binge eating, anorexia, bulimia — approximately 30–40%. PMDD is substantially overrepresented. Suicidality and self-harm risk is elevated four to six times above the general population rate, which mandates systematic assessment at every mental health contact. Sleep disorders — particularly insomnia and obstructive sleep apnoea — are common. ASD overlap is well recognised. A new ADHD diagnosis warrants concurrent screening for mood disorder, eating disorder, sleep disorder, and suicide risk.
What non-medication strategies help alongside stimulant treatment?

CBT for ADHD — adapted protocols targeting executive function, emotion regulation, and time management — has moderate evidence and is fundable through Better Access psychology (MBS 80000–80020). ADHD coaching offers practical accountability and skill-building. Sleep optimisation is high yield: sleep debt amplifies inattention and emotional dysregulation. Regular aerobic exercise has a demonstrated acute benefit on attention. Iron, B12, and vitamin D correction matters particularly in menstruating women where deficiency is common. For cycle-sensitive women, managing PMDD with a luteal-phase SSRI or oestrogen-containing contraception can substantially reduce cyclical symptom worsening.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.